Department of Microbiology and Immunology, School of Medicine, Pusan National University, Yangsan-si, Gyeongsangnam-do 626-770, Republic of Korea.
Int J Oncol. 2012 Sep;41(3):1139-47. doi: 10.3892/ijo.2012.1508. Epub 2012 Jun 6.
SEREX has proven to be a powerful method that takes advantage of the presence of spontaneous humoral immune response in some cancer patients. In this study, immunoscreening of normal testis and two ovarian cancer cell line cDNA expression libraries with sera from ovarian cancer patients led to the isolation of 75 independent antigens, designated KP-OVA-1 through KP-OVA-75. Of these, RT-PCR showed KP-OVA-52 to be expressed strongly in normal testis, in ovarian cancer cell lines (3/9) and in ovarian cancer tissues (1/17). The expression of KP-OVA-52 in cancer cells is also induced by the demethylating agent 5‑aza‑2'‑deoxycytidine (ADC). To test immunogenicity, we used the Serum Antibody Detection Assay (SADA) to analyze anti-IgG antibodies against the 75 antigens that were initially isolated by SEREX. Four of the 75 antigens (KP‑OVA‑25, KP‑OVA‑35, KP‑OVA‑68 and KP‑OVA‑73) reacted exclusively with sera from cancer patients. However, KP‑OVA‑52 reacted with 1 of 20 ovarian cancer sera. These data suggest that the KP-OVA-52 can be considered a novel CT antigen that is regulated by DNA methylation.
SEREX 已被证明是一种强大的方法，它利用了一些癌症患者中自发体液免疫反应的存在。在这项研究中，用卵巢癌患者的血清免疫筛选正常睾丸和两种卵巢癌细胞系 cDNA 表达文库，导致分离出 75 个独立的抗原，命名为 KP-OVA-1 到 KP-OVA-75。其中，RT-PCR 显示 KP-OVA-52 在正常睾丸、卵巢癌细胞系（3/9）和卵巢癌组织（1/17）中强烈表达。癌症细胞中 KP-OVA-52 的表达也被去甲基化剂 5-aza-2'-脱氧胞苷 (ADC) 诱导。为了测试免疫原性，我们使用血清抗体检测分析（SADA）分析了最初通过 SEREX 分离的 75 种抗原的抗 IgG 抗体。在最初分离的 75 种抗原中，有 4 种（KP-OVA-25、KP-OVA-35、KP-OVA-68 和 KP-OVA-73）仅与癌症患者的血清反应。然而，KP-OVA-52 与 20 个卵巢癌血清中的 1 个反应。这些数据表明，KP-OVA-52 可以被认为是一种新的 CT 抗原，受 DNA 甲基化调控。
